BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35265528)

  • 1. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer.
    Li S; Zhang G; Lu Y; Zhao T; Gao C; Liu W; Piao Y; Chen Y; Huang C; Chang A; Hao J
    Front Oncol; 2022; 12():841819. PubMed ID: 35265528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma.
    Li S; Xu H; Wang W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Wu C; Liu L
    Cancer Manag Res; 2019; 11():3327-3337. PubMed ID: 31114368
    [No Abstract]   [Full Text] [Related]  

  • 6. A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma.
    Zhang LX; Chen L; Xu AM
    Front Oncol; 2020; 10():583. PubMed ID: 32426277
    [No Abstract]   [Full Text] [Related]  

  • 7. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma.
    Li X; Li S; Liu L; Hong J; Zhao T; Gao C
    J Cancer; 2020; 11(1):9-15. PubMed ID: 31892968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection.
    Sugawara T; Ban D; Nishino J; Watanabe S; Maekawa A; Ishikawa Y; Akahoshi K; Ogawa K; Ono H; Kudo A; Tanaka S; Tanabe M
    PLoS One; 2021; 16(4):e0249885. PubMed ID: 33844700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of C-reactive protein-to-prealbumin ratio in predicting early recurrence in resectable pancreatic cancer.
    Kwon CH; Seo HI; Kim DU; Han SY; Kim S; Lee NK; Hong SB; Ahn JH; Park YM; Noh BG
    Korean J Clin Oncol; 2023 Jun; 19(1):11-17. PubMed ID: 37449394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A scoring model for predicting early recurrence of gastric cancer with normal preoperative tumor markers: A multicenter study.
    Zheng CY; Wu J; Chen CS; Huang ZN; Tang YH; Qiu WW; He QC; Lin GS; Chen QY; Lu J; Wang JB; Lin JX; Cao LL; Lin M; Tu RH; Xie JW; Li P; Huang CM; Zheng YH; Zheng CH
    Eur J Surg Oncol; 2023 Nov; 49(11):107094. PubMed ID: 37797381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy and its nomogram-based prediction.
    Pu N; Yin H; Zhao G; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Cancer; 2019; 10(24):5935-5943. PubMed ID: 31762803
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection.
    Zhang LP; Ren H; Du YX; Wang CF
    World J Gastroenterol; 2020 Dec; 26(46):7382-7404. PubMed ID: 33362391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
    Kim DW; Lee SS; Kim SO; Kim JH; Kim HJ; Byun JH; Yoo C; Kim KP; Song KB; Kim SC
    Radiology; 2020 Sep; 296(3):541-551. PubMed ID: 32662759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Salmiheimo A; Mustonen H; Stenman UH; Puolakkainen P; Kemppainen E; Seppänen H; Haglund C
    PLoS One; 2016; 11(9):e0163064. PubMed ID: 27632196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the physiobiological parameter-based grading system for predicting the long-term prognosis after curative surgery for resectable pancreatic cancer.
    Abe T; Amano H; Kobayashi T; Hattori M; Hanada K; Nakahara M; Ohdan H; Noriyuki T
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):613-619. PubMed ID: 32978015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
    Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
    Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.